Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe in a randomized prospective study the effectiveness
and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of
living donor (LD) kidneys, compared with the investigators standard treatment protocol of
Zenapax® and maintenance immunosuppression.